Exelixis

Exelixis, NBE join forces for discovery and development of ADCs for cancer
Exelixis, NBE join forces for discovery and development of ADCs for cancer
Pharmaceutical Business Review
Exelixis
NBE Therapeutics
antibody-drug conjugate
oncology
Flag link:
Exelixis Files for Cabometyx Combo in First-Line Kidney Cancer
Exelixis Files for Cabometyx Combo in First-Line Kidney Cancer
Yahoo/Zacks.com
Exelixis
Cabometyx
FDA
kidney cancer
renal cell carcinoma
Bristol-Myers Squibb
Opdivo
Flag link:
Exelixis initiates phase 3 trial of Cabozantinib/Atezolizumab combo in prostate cancer
Exelixis initiates phase 3 trial of Cabozantinib/Atezolizumab combo in prostate cancer
Pharmaceutical Business Review
Exelixis
cabozantinib
Cabometyx
Tecentriq
metastatic castration-resistant prostate cancer
clinical trials
Flag link:
Exelixis lands PhIII kidney cancer win with Bristol Myers in their hunt for $4 billion
Exelixis lands PhIII kidney cancer win with Bristol Myers in their hunt for $4 billion
Endpoints
Bristol-Myers Squibb
Opdivo
Exelixis
Cabometyx
renal cell carcinoma
kidney cancer
clinical trials
Flag link:
2 Biotechs Battling Against Kidney Cancer
2 Biotechs Battling Against Kidney Cancer
Motley Fool
kidney cancer
Nektar
Exelixis
Flag link:
Why AnaptysBio, bluebird bio, and Exelixis Shares Rebounded Last Friday
Why AnaptysBio, bluebird bio, and Exelixis Shares Rebounded Last Friday
Motley Fool
pharma stocks
AnaptysBio
Bluebird Bio
Exelixis
COVID-19
Flag link:
Asco-GU 2020: revving up for Peloton deal validation
Asco-GU 2020: revving up for Peloton deal validation
EP Vantage
ASCO-GU 2020
Merck
Peloton Therapeutics
Exelixis
Flag link:
Exelixis Reports Positive Results in Metastatic Castration-Resistant Prostate Cancer Study
Exelixis Reports Positive Results in Metastatic Castration-Resistant Prostate Cancer Study
Motley Fool
Exelixis
prostate cancer
metastatic castration-resistant prostate cancer
cabozantinib
Cabometyx
Flag link:
JP Morgan Preview: Small, Medium and Large, with a Lot of M&A Speculation
JP Morgan Preview: Small, Medium and Large, with a Lot of M&A Speculation
BioSpace
JPMHC 2020
M&A
Exelixis
Intercept Pharmaceuticals
Avidity Biosciences
Theravance
Moderna Therapeutics
Kodiak Sciences
Flag link:
Eyeing second Japanese approval, Daiichi and Exelixis announce positive pivotal for kidney drug
Eyeing second Japanese approval, Daiichi and Exelixis announce positive pivotal for kidney drug
Endpoints
Daiichi Sankyo
Exelixis
clinical trials
diabetic nephropathy
Minnebro
Flag link:
Renal Cell Carcinoma Space in Focus: Some Key Developments
Renal Cell Carcinoma Space in Focus: Some Key Developments
Yahoo/Zacks.com
renal cell carcinoma
kidney cancer
Exelixis
Roche
Merck
Aveo Oncology
Flag link:
Exelixis Hits Blockbuster Status
Exelixis Hits Blockbuster Status
Motley Fool
Exelixis
cabozantinib
Cabometx
kidney cancer
liver cancer
Cometriq
thyroid cancer
Flag link:
Exelixis Bolsters Pipeline in Deal with India's Aurigene
Exelixis Bolsters Pipeline in Deal with India's Aurigene
BioSpace
Exelixis
Indian
Aurigene
Cabometyx
Flag link:
Roche/Exelixis' Cotellic fizzles in pivotal melanoma study
Roche/Exelixis' Cotellic fizzles in pivotal melanoma study
Endpoints
Roche
Exelixis
Cotellic
Tecentriq
clinical trials
advanced melanoma
Flag link:
After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal
After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal
Endpoints
Exelixis
Cabometyx
ICON-2
Iconic Therapeutics
antibody-drug conjugate
Flag link:
Where Will Gilead Sciences Spend Its Cash?
Where Will Gilead Sciences Spend Its Cash?
Motley Fool
Gilead Sciences
M&A
Atara
Exelixis
Flag link:
Exelixis initiates phase 3 trial of cabozantinib in advanced renal cell carcinoma
Exelixis initiates phase 3 trial of cabozantinib in advanced renal cell carcinoma
Pharmaceutical Business Review
Exelixis
clinical trials
cabozantinib
Cabometyx
advanced renal cell carcinoma
Flag link:
3 Cancer Treatment Stocks on a Growth Trend
3 Cancer Treatment Stocks on a Growth Trend
Motley Fool
Geron
AbbVie
Exelixis
cancer
Flag link:
Exelixis Proves Being Second Can Work Out Well
Exelixis Proves Being Second Can Work Out Well
Motley Fool
Exelixis
Bristol-Myers Squibb
Cabometyx
kidney cancer
Flag link:
Exelixis (EXEL) to Report Q4 Earnings: What's in Store?
Exelixis (EXEL) to Report Q4 Earnings: What's in Store?
Yahoo/Zacks.com
Exelixis
earnings
Flag link:

Pages